BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36210541)

  • 21. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice.
    Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S
    Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
    Okumura M; Sasaki Y; Yoshiyama T; Matsuda S; Osawa T; Morimoto K; Yanai H; Kurasima A; Ogata H; Gotoh H
    Kekkaku; 2015 Oct; 90(10):665-70. PubMed ID: 26821395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistant Mycobacterium tuberculosis in Korean isolates.
    Carpenter JL; Covelli HD; Avant ME; McAllister CK; Higbee JW; Ognibene AJ
    Am Rev Respir Dis; 1982 Dec; 126(6):1092-5. PubMed ID: 6185025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
    Furin JJ; Du Bois J; van Brakel E; Chheng P; Venter A; Peloquin CA; Alsultan A; Thiel BA; Debanne SM; Boom WH; Diacon AH; Johnson JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6591-6599. PubMed ID: 27550361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
    Eltringham IJ; Wilson SM; Drobniewski FA
    J Clin Microbiol; 1999 Nov; 37(11):3528-32. PubMed ID: 10523547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of a reverse dot blot hybridization assay for simultaneous detection of the resistance of four anti-tuberculosis drugs in Mycobacterium tuberculosis isolated from China.
    Wan L; Guo Q; Wei JH; Liu HC; Li MC; Jiang Y; Zhao LL; Zhao XQ; Liu ZG; Wan KL; Li GL; Guan CX
    Infect Dis Poverty; 2020 Apr; 9(1):38. PubMed ID: 32299480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
    Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of isoniazid-resistant pulmonary tuberculosis.
    Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Lim SY; Lim SY; Koh WJ
    BMC Infect Dis; 2008 Jan; 8():6. PubMed ID: 18211720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
    Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. INTENSIVE TREATMENT OF A CAPTIVE BORNEAN ELEPHANT (
    Suga S; Mukai Y; Ishikawa S; Yoshida S; Paudel S; Wada T
    J Zoo Wildl Med; 2021 Jan; 51(4):1062-1066. PubMed ID: 33480591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for chemotherapy of tuberculosis and current recommendations.
    Kumar L
    Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486
    [No Abstract]   [Full Text] [Related]  

  • 38. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular mechanisms of multidrug resistance in Mycobacterium tuberculosis].
    Taniguchi H
    J UOEH; 2000 Sep; 22(3):269-82. PubMed ID: 11019393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line anti-tuberculosis drug resistance trends of Mycobacterium tuberculosis complex isolates. A tertiary hospital study in Turkey.
    Yazısız H; Hırçın Cenger D; Yazısız V; Kılıç L; Altın S
    Tuberk Toraks; 2019 Jun; 67(2):92-101. PubMed ID: 31414639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.